Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. The first product, Alkindi®, is being rolled out through key EU markets, and sales have exceeded the £1.0m mark. Despite unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019. It has also allowed DNL to revise the primary endpoint in the protocol for the US Chronocort Phase III trial.
If you'd like to be introduced to the team at Diurnal Group Plc, get in touch.Request a meeting